Daily Ards Research Analysis
Analyzed 11 papers and selected 3 impactful papers.
Summary
Analyzed 11 papers and selected 3 impactful articles.
Selected Articles
1. Hybrid additive manufacturing-based assembly of sacrificial isomalt scaffolds and gas exchange membranes for microfluidic artificial lung development.
The authors introduce a hybrid additive manufacturing workflow that combines extrusion-printed sacrificial isomalt scaffolds with spin-coated PDMS membranes to build microfluidic artificial lungs. The process yielded multilayer oxygenators (11 alternating blood/gas layers with 121 μm membranes) with complete channel patency, 0% rejection, and in vitro evidence of high oxygen-transfer efficiency.
Impact: This engineering advance addresses manufacturability and scalability bottlenecks for microfluidic oxygenators, a promising alternative to invasive ventilation in fragile neonates.
Clinical Implications: If translated, microfluidic oxygenators with low priming volume could reduce ventilator-induced lung injury and potentially defer or reduce the need for ECMO in preterm infants with severe respiratory failure.
Key Findings
- Developed a hybrid additive-manufacturing method combining extrusion-printed sacrificial isomalt scaffolds with spin-coated PDMS membranes.
- Fabricated oxygenators with 11 alternating blood/gas layers separated by thin (121 μm) membranes.
- Achieved complete channel patency with a 0% rejection rate and demonstrated high in vitro oxygen-transfer efficiency.
Methodological Strengths
- Solvent-free, biocompatible fabrication eliminating toxic solvents and enabling complete channel patency.
- Scalable multilayer assembly demonstrated with zero device rejection and defined membrane thickness control.
Limitations
- Evidence is limited to in vitro evaluation; no in vivo or clinical testing reported.
- Hemocompatibility, thrombogenicity, and long-term durability were not assessed.
Future Directions: Preclinical large-animal testing to quantify gas exchange under physiological flow, hemocompatibility and durability assessments, and integration with neonatal circuits to inform first-in-human feasibility.
Preterm neonates are susceptible to respiratory distress syndrome (RDS) due to their underdeveloped lungs and require mechanical ventilation. Microfluidic blood oxygenators (MBOs) are a suitable alternative due to their small priming volume and their potential to reduce iatrogenic effects of ventilation. Current MBOs use lithographic fabrication that limits their manufacturability due to scalability and integration issues. Additive-manufacturing has been recently explored to overcome fabrication challenges, but has its own limitations in realizing scalable thin-membrane devices with high degree of channel patency. This work presents a new hybrid additive-manufacturing strategy for artificial lungs, by combining extrusion printing of sacrificial isomalt scaffolds with spin-coating of thin polydimethylsiloxane membranes. It eliminates the use of synthetic polymers or toxic solvents, yielding complete channel patency and biocompatibility. Using this scalable process, oxygenators with 11 alternating blood/gas layers separated by thin (121 µm) membranes were manufactured, achieving complete channel patency and a 0% rejection rate. In vitro evaluation showed reduced form-factor while achieving a high oxygen-transfer efficiency of 184 mL O
2. Integrated toxicological analysis links air pollution-associated acute respiratory distress syndrome signatures to benzo[a]pyrene-induced acute lung injury.
By integrating time-varying clinical data, computational analyses, and in vivo validation, the study connects ambient particulate pollution with ARDS by showing positive associations with ARDS admissions and mechanistic alignment to benzo[a]pyrene-induced acute lung injury. The work advances understanding of how specific pollutants may trigger severe inflammatory lung injury.
Impact: It provides mechanistic links between air pollution and ARDS, informing prevention strategies and potential biomarker or target discovery.
Clinical Implications: Findings support public health policies to reduce particulate exposure, risk communication for vulnerable populations, and development of exposure-related biomarkers to identify high-risk patients for ARDS.
Key Findings
- Monthly ARDS hospital admissions were positively associated with ambient particulate matter concentrations.
- Bioinformatic and molecular interaction analyses implicated pathways consistent with pollution-driven inflammatory injury.
- In vivo toxicological validation demonstrated that benzo[a]pyrene-induced acute lung injury recapitulates ARDS-associated signatures.
Methodological Strengths
- Multimodal design integrating clinical time-series, computational biology, and in vivo toxicology.
- Mechanistic validation using a defined pollutant (benzo[a]pyrene) to link exposure with lung injury signatures.
Limitations
- Observational association between pollution and ARDS admissions cannot establish causality.
- Generalizability may be constrained by local exposure patterns and the benzo[a]pyrene model not fully recapitulating human ARDS heterogeneity.
Future Directions: Prospective exposure cohorts with individual-level monitoring, validation of pollution-linked biomarkers in patients, and interventional studies assessing air quality improvements on ARDS incidence.
Acute respiratory distress syndrome (ARDS) is associated with high mortality, and increasing evidence suggests that air pollution may contribute to its development. However, the molecular mechanisms linking pollutant exposure to severe inflammatory lung injury remain incompletely understood. In this study, we integrated local clinical association data, bioinformatic analyses, molecular interaction prediction, and in vivo toxicological validation to investigate potential mechanisms underlying pollution-associated respiratory injury. Monthly hospital admissions for ARDS were positively associated with ambient particulate matter concentrations (PM
3. Leveraging Administrative Health Data to Capture Rare Adverse Drug Reactions: Identifying Pediatric Patients With Trimethoprim-Sulfamethoxazole Acute Respiratory Distress Syndrome.
Using features from two local TMP-SMX–associated pediatric ARDS cases, the authors built a standardized phenotype mapped to PHIS and prioritized candidate encounters via a scoring system. Internal and external validations showed known cases consistently ranked within the top five at their institutions, demonstrating feasibility for multi-institutional identification of rare ADRs.
Impact: This pragmatic informatics approach enables targeted case review for rare, severe drug-induced ARDS across hospitals, accelerating pharmacovigilance and future research.
Clinical Implications: Hospitals can deploy a standardized phenotype to flag likely TMP-SMX ARDS cases for prompt review, improve ADR reporting, and inform risk–benefit decisions about TMP-SMX in children.
Key Findings
- Developed a clinical phenotype for TMP-SMX–associated pediatric ARDS mapped to standardized elements in PHIS.
- Internal validation: two known local cases ranked 1st and 3rd on center-specific top-10 candidate lists.
- External validation at three hospitals: known cases ranked 3rd, 3rd, and 5th on their top-10 lists.
- Phenotype features included ECMO >100 days, early air leak, tracheostomy, and hospitalization >440 days.
Methodological Strengths
- Use of a national standardized database (PHIS) with phenotype-driven prioritization.
- Both internal and external validations demonstrated reproducibility across institutions.
Limitations
- Phenotype derived from very few seed cases may miss atypical presentations.
- Reliance on administrative data and coding requires manual chart review to confirm cases.
Future Directions: Refine phenotype criteria with additional confirmed cases, incorporate natural language processing of clinical notes, and extend to other suspected drug-induced ARDS phenotypes.
Rare adverse drug reactions (ADRs) are underrecognized and underreported in the electronic medical record (EMR). These events often require clinical review, making systematic identification challenging. The study aim was to develop an approach to prioritize identification and validation of a rare ADR to trimethoprim-sulfamethoxazole causing acute respiratory distress syndrome (TMP-SMX ARDS) across medical institutions. We developed a clinical phenotype based on 2 local TMP-SMX ARDS cases mapped to standardized elements of a national comparative healthcare database (PHIS). We validated identification of TMP-SMX ARDS at scale across medical institutions. A set of scoring criteria was created to prioritize cases and generate a center-specific top 10 list of candidate encounters. External validation at 3 PHIS contributing hospitals with a known TMP-SMX ARDS case was performed by reviewing the top 10 candidate list for the known case. The review period was January 1, 2012-January 1, 2025. EMR data extracted from 2 TMP-SMX ARDS cases included patients that both required extracorporeal membrane oxygenation for > 100 days, experienced air leak early in hospital presentation, required tracheostomy placement, and were hospitalized for > 440 days. Based on the TMP-SMX ARDS phenotype, the local cases ranked 1st and 3rd on the PHIS generated top 10 candidate list for internal validation. For external validation, known cases were identified on their respective hospital top 10 lists, ranking 3rd, 3rd, and 5th. Applying a TMP-SMX ARDS phenotype to a national health care database paired with clinical review of candidate cases may be an effective approach to identify underrecognized ADRs. Rare adverse drug reactions (ADRs) are often not clearly documented in the medical record, making identification of such events challenging. Clinical review of ADR cases is often required to confirm a case, making a systematic approach across several hospitals difficult. The purpose of this project was to develop a way to identify and confirm a rare ADR to a medication called trimethoprim‐sulfamethoxazole that was associated with causing lung failure (TMP‐SMX ARDS) at different hospitals. We mapped the characteristics of 2 TMP‐SMX ARDS cases that occurred at our hospital to a large national healthcare database to create a phenotype. We then applied the phenotype to see how well it could identify the 2 known local cases (i.e., internal validation) and 3 known cases at outside medical institutions (external validation). Using the developed TMP‐SMX ARDS phenotype, the local cases ranked 1st and 3rd on a generated top 10 list of possible cases. For external validation, the known cases were identified on their respective hospital top 10 lists, ranking 3rd, 3rd, and 5th. We conclude that this approach of building a clinical phenotype based on very few cases at a single institution can then be applied to a large database to identify likely cases at other hospitals. The ability to identify highly likely cases could assist in making the clinical review of potential new cases more effective and efficient to assist in studying rare, underrecognized ADRs.